Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.20 | 79.30 | 0.91% |
| CAC 40 | 7,805.91 | 42.07 | 0.54% |
| DAX 40 | 24,262.63 | 171.01 | 0.71% |
| Dow JONES (US) | 42,556.80 | 37.16 | 0.09% |
| FTSE 100 | 8,803.67 | 16.65 | 0.19% |
| HKSE | 23,654.03 | 141.54 | 0.60% |
| NASDAQ | 19,450.07 | 51.11 | 0.26% |
| Nikkei 225 | 37,747.45 | 300.64 | 0.80% |
| NZX 50 Index | 12,494.71 | 167.48 | 1.36% |
| S&P 500 | 5,980.12 | 9.75 | 0.16% |
| S&P/ASX 200 | 8,541.80 | 75.10 | 0.89% |
| SSE Composite Index | 3,376.20 | 14.23 | 0.42% |